chrisvoncsefalvay/vaers-outcomes huggingface dataset:
12hrs post. Full covid symtoms incl fever, severe aches/headache, extrem fatigue, loss appetite. 48 hrs post minor headache/body ache, fatigue; 12hrs post. Full covid symtoms incl fever, severe aches/headache, extrem fatigue, loss appetite. 48 hrs post minor headache/body ache, fatigue; 12hrs post. Full covid symtoms incl fever, severe aches/headache, extrem fatigue, loss appetite. 48 hrs post minor headache/body ache, fatigue; 12hrs post. Full covid symtoms incl fever, severe aches/headache, extrem fatigue, loss appetite. 48 hrs post minor headache/body ache, fatigue; 12hrs post. Full covid symtoms incl fever, severe aches/headache, extrem fatigue, loss appetite. 48 hrs post minor headache/body ache, fatigue; This is a spontaneous report from a contactable consumer (Patient). A 59-years-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Strength: unknown, Lot Number: EN6208), via an unspecified route of administration, administered in right arm on 25Mar2021 at 12:00 as Dose 2, SINGLE for covid-19 immunization (Age at vaccination was 59-year-old). The patient medical included Afib, kidney cancer, uc, hip & knee pain from unknown start date and unknown start date. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient having allergies with Shellfish and pine. The patient did not administered other vaccine within four weeks. Concomitant medications include Lisinopril, Eliquis, Sertraline, Metoprolol start dates and stop dates were not mentioned. The patient received first dose of BNT162B2 (PFIZ-ER-BIONTECH COVID-19 VACCINE, Lot number: EN6198) in left arm on 04Mar2021 at 13:00 for covid-19 immunisation. On 26Mar2021 at 01:00 the patient had covid symptoms incl fever, severe aches, headache, extreme fatigue, loss appetite. The patient did not receive ant treatment for the events. The patient reporting events as non-serious. The outcome of the events was recovering.  No follow-up attempts are needed. No further information is expected.
8-year-old female, has hypertension, being worked up for anemia, as well as has hypothyroidism, has not felt well in the last 1 week.  She feels weak and dizzy, has no energy.  She apparently underwent blood transfusion in the earlier part of this month.  She did not feel much better.  She has episodes of abdominal pain and black stools.  Apparently, she has been taking iron therapy.  Patient underwent workup, which reveals hemoglobin of 8.8.  Electrolytes reveal unremarkable findings.  She was tested for COVID, which was found to be positive.CT chest abdomen  was consistent with atypical pneumonia of COVID-19.Patient admited for further management.
Intractable headache; Lowgrade fever; Chills; Fatigue; Malaise; This is a spontaneous report from a contactable Other HCP (patient). A 34-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EN5318), via an unspecified route on 04Feb2021 at 12:30 (at the age of 34-years) as 2nd dose, single in left arm for COVID-19 immunisation. The patient's medical history was not reported. The patient did not receive any other vaccine in four weeks of vaccination. Concomitant medication(s) included bupropion hydrochloride (WELLBUTRIN). The patient previously received first dose of BNT162B2 (Lot number: EL0142), via an unspecified route on 14Jan2021 at 12:30 (at the age of 34-years) as 1st dose, single in left arm for COVID-19 immunisation. Patient was not diagnosed with COVID prior vaccination. The patient was not pregnant at the time of vaccination. On 05Feb2021 at 12:00, the patient experienced intractable headache, chills, low grade fever, fatigue and malaise. Post vaccination the patient was not tested for COVID. Treatment was not received for the reported events. The outcome of the events was recovering.  Follow-up attempts are completed. No further information is expected.
Fever ranging from 99.9-101.7 for 24 hrs, headache, joint/body aches, soreness, redness, and swelling at and below injection site.
Upper torso rash. Hot-to-touch with white blotches. Right upper chest raised red rash 5" in diameter that keeps coming back off and on.
pt recv vax 3JUL95 & 23MAY96 pt devel rash on arms & presented to MD;rash was described as a typical chickenpox rash w/20 to 50 lesions;no fever was noted;No further details were provided;
Drawing up reconstituted vx accidentally splashed into eye; Vx accidentally splashed into her eye; This case was reported by a pharmacist via call center representative and described the occurrence of occupational exposure while preparing product for administration in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 27th April 2022, the patient received Shingrix. On 27th April 2022, unknown after receiving Shingrix, the patient experienced occupational exposure while preparing product for administration and exposure via eye contact. On an unknown date, the outcome of the occupational exposure while preparing product for administration and exposure via eye contact were unknown.       Additional Information: GSK receipt date: 29 Apr 2022 Reporter's comment: The reporter was an HCP (pharmacist). The HCP reported that a nurse was drawing up reconstituted Shingrix and it accidentally splashed into her eye. She rinsed her eye immediately with water and was asymptomatic. She has nothing else to report. The reporter consented to follow up. The reporter had limited information. Patient initials and DOB unknown. Additional supportive information: Reconstituted Shingrix was accidentally splashed into pharmacist's eye, which led to occupational exposure while preparing product and exposure via eye contact.
This spontaneous report has been received from a nurse practitioner regarding a patient of unknown age and gender. The patient's concurrent condition, medical history and concomitant medications were not reported. On 19-NOV-2013, the patient received improperly stored VARIVAX dose 1, from lot # H018451, expiry date 09-OCT-2014 (dose, vaccination site, route unknown). No adverse effects were reported. The reporter stated that inconsistencies in storage temperature were identified on extensive review and records. The reporter stated that vaccine was not thawed. The nurse practitioner reported that there was insufficient data to provide 100 percent assurance on vaccine stability. This is one of several reports received from the same reporter. Additional information has been requested.
The first dose was administrated on 2019./No 2nd dose was administrated yet.; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose of Shingrix on an unknown date in 2019).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. No adverse event was reported after 1st dose.  Till the time of reporting the patient did not receive 2nd dose, which led to incomplete course of vaccination. Patient's identifiers, LOT number, expiration date and vaccination date was not provided. The health care professional needed to look for all the information regarding the first dose. The reporter consented to follow up
Patient's mother brought patient into office on 1-20-16 and stated that patient's left arm was swollen and red at the site that injections were given on 1-18-16. Denies fever. Mother states she gave patient Ibuprofen for pain on 1-18-16.
CHILLS, BODY ACHES, FEVER, MUSCLE WEAKNESS, JOINT PAIN, PROLIA INJECTIONS, STOMACHE PAIN
Continued pain at injection site for at least 1 week, developed warmth and itching at injection site along with painful underarm lymph nodes on injected arm.
test for microscopic chlamydia came back positive; recurring yeast infections; all of my lymph nodes became swollen/it became very apparent/my lymph nodes had become all infected; This is a spontaneous report received from a contactable consumer. The reporter is the patient. A 32-year-old patient received BNT162b2 (BNT162B2), on 25Jan2022 at 14:00 as dose 3 (booster), single (Lot number: FR9896) at the age of 32 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Overactive immune system" (unspecified if ongoing); "Gene mutation" (unspecified if ongoing), notes: Cold Urticaria; "Cold Urticaria" (unspecified if ongoing); "known allergies " (unspecified if ongoing), notes: many things long list. Concomitant medication included: ALLEGRA 24 HOUR. Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: ER8730, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 02Apr2021, for COVID-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EN6207, Location of injection: Arm Left, Vaccine Administration Time: 03:00 PM), administration date: 12Mar2021, for COVID-19 immunization. Patient did not receive other vaccine in four weeks. Patient did not have covid prior vaccination. She tested covid post vaccination and got a negative result. After patient received the covid-19 booster all of her lymph nodes became swollen since 25Jan2022 and within the next couple of weeks it became very apparent that she needed to get to it hospital or urgent Care. She reached out to the CDC and recently they reached back out to her and told her to report to here. She was treated for the lymph nodes (antibiotics for the lymph nodes/ shot) they said that her lymph nodes had become all infected, the lymph nodes then went down everything appeared normal. She then started to experience recurring yeast infections, she was then tested for Sexually transmitted diseases (STDs). She stated that she has not been sexually active with absolutely anybody since 2018 and she was tested for STDs before that and she tested negative for absolutely everything. But after she received this booster and after she had that reaction, her test for microscopic chlamydia came back positive. She then tried to reach out to see if the people who participated in the creation of the vaccine had been tested for microscopic chlamydia mycoplasma. Patient reported that the events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Life threatening illness (immediate risk of death from the event). The patient underwent the following laboratory tests and procedures: Chlamydia test: came back positive; SARS-CoV-2 test: Negative; Sexually transmitted disease test: negative, notes: tested negative for absolutely everything. Therapeutic measures were taken as a result of lymph gland infection. Outcome of lymph nodes became swollen, lymph nodes had become all infected was recovering, outcome of other events was unknown.
Patient received Pfizer vaccine and stated she began feeling flushed, felt like she had a lump i her throat and a metallic taste in her mouth..  Transported to ED,  administered diphenhydramine, famotidine, and methylprednisolone, significant improvement after medications. Patient discharged in stable condition.
Pt recvd vax on 7JUN92 & devel rash behind legs, & lab eval revealed that pt was pos for Hep C & neg in supplemental testing; No further details were provided;
Client in observation unit post vaccine, client complaining of  headache, anxiety and possible panic attack. Client assessed by NP  feels lightheaded vitals obtained HR 94, 02sat 99%. Client left site with her daughter at her side at 1601.
This spontaneous report has been received from a physician, concerning a 9 week old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not provided. On 17-JUN-2018, the patient was vaccinated with the first dose of PEDVAXHIB and, on 19-JUN-2018, the patient was vaccinated with the second dose of PEDVAXHIB (route, lot number and expiration date were not provided for both doses) for prophylaxis. No adverse effects reported.
Patient states she bled when the vaccines were given on 10/4/18. She developed increasing redness, swelling, and pain around the injection site over 2 days. She went to the physician and was prescribed KEFLEX 500mg, 1 tid for 5 days on 10/6/18.
At approx.  10:30 a.m. on 12/10/21,  I began to have difficulty with my vision which then progressed into flashing colored lights in my peripheral vision.  At approx. 11:00, an intense, sharp headache begin on the right side of my head from my ear to my right eye. This lasted approx. 3 hours and gradually diminished around 4 p.m.  During this time, I visited my optometrist who ruled out any causes of sight change originating in my eyes.  After contacting the doctor on call at PCP office, I was advised to take a low dose aspirin during weekend and go to ER if another event occurred. On 12/14/21 p, a CT scan was performed to rule out possible stroke. None was found.
Whole body aches; Sore arm at injection site; Chills; Muscle fatigue; Headache; Nausea; Generally feeling unwell; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the right arm on 15Apr2021 at 16:15 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included loratadine (CLARITIN) or acetylsalicylic acid, caffeine, paracetamol (EXCEDRIN) for unknown indication from an unknown date. The patient previously received ceftriaxone (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 13:00 the patient experienced whole body aches, sore arm at injection site, chills, muscle fatigue, headache and generally feeling unwell. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events whole body aches, sore arm at injection site, chills, muscle fatigue, headache and generally feeling unwell were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Anaphylactic reaction.  Facial itching, copious mucous, cough, vomit, hives, and mild tongue swelling.
Approximately 2 hrs after injection, I started coughing a lot, then a few hrs later my head started filling up, nose running and sneezing, then headache, and stuffiness, aches also.  It was like the flu or a cold squeezed from a week to all in one day.  I took ADVIL PM and went to bed.  Next morning I was fine.
ALMOST LOST; This spontaneous report received from a consumer via a company representative via social media concerned a male of unspecified age, race and ethnicity. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported) dose was not reported, 1 total administered on SEP-2021 for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On 23-SEP-2022, an year after vaccination, the patient experienced almost lost. It was reported that "We almost lost my brother in law today bc of their vax he took an year ago. They're covering it up with saying that it's genetic". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of almost lost was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20220948253-covid-19 vaccine ad26.cov2.s-almost lost. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). Therefore, this event(s) is considered unassessable.
Bones ache eyes out of focus extremely Dizzy nausea cannot keep any food or water down cannot focus or remember very foggy cannot walk forward in a straight line have to hold onto the walls and doors or crawl head aches right kidney aches knees don?t work
This spontaneous report was received from a physician regarding a female patient of unknown age. Information on medical history, past drugs, concurrent conditions, concomitant medications were not reported. On 17-AUG-2016, the patient was vaccinated with GARDASIL 9 injection, (lot number, Expiry date were unknown) for vaccination. On an unspecified date, the patient experienced persistent headache which was lasting for two weeks. Treatment was not given. No lab diagnostic studies were performed. The outcome of headache was unknown. The reporter did not assess the causal relation of event with respect to GARDASIL 9. Additional information has been requested.
Upon internal review, a significant correction was performed on 26 April 2017 to add the correct product INFLUENZA QUADRIVAL A-B VACCINE and Class priority changed from Class 3 to Class 1. Initial report was received on 03 October 2013 from a nurse. A 68 year-old male patient with a history of asthma had received FLUZONE QUADRIVALENT (lot number, route, site and date of administration not reported) and 12 hours later experienced respiratory arrest and was hospitalized. The patient was stable but was still hospitalized. No further information was available at the time of the report. The patient's outcome was not recovered. Documents held by sender: none. Addendum: 02 March 2017 Upon second medical examination of the case during internal review, a significant correction was performed on 26 April 2017 to add the correct product INFLUENZA QUADRIVAL A-B VACCINE and Class priority changed from Class 3 to Class 1. Sender's Comments: Limited information provided in this case is not sufficient for the case assessment. A description of the event, final diagnosis and complementary investigation results are needed to fully assess the case.
Swelling. Hives. Sore Throat. 10 days Treated with Steroid taper (Prednisone).
This spontaneous report as received from a healthcare worker refers to a two patients of unknown age and gender. On 23-JUL-2015, those two patients were vaccinated with a dose of improperly stored (Oka/Merck) VARIVAX (lot # L007225, exp. date: 03-MAR-2017) (doses and routes were not reported). No adverse effect reported. Additional information has been requested.
No adverse effects reported.; One female Patient was administered improperly stored M-M-R II; This spontaneous report was received from The Office Manager referring to a 72 year old  female patient. The patient's medical history, concurrent conditions, concomitant medications, and historical drugs were not reported.  On 15-JUL-2019, the patient was administered an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live rHA recombinant Human albumin (rHA) (M-M-R II) (Strength, route, dose, frequency, and anatomical location were unknown) with lot # R031628 and expiration date 01-NOV-2020.   The administered dose of the vaccine experienced a total time and highest temperature above 47°F (51.1 F, multiple) degrees Fahrenheit for 29 hours. There was a digital data logger invloved, but there was no previous temperature excursion. No adverse effects were reported.
This is a spontaneous report from a Pfizer-sponsored program, Pfizer RXPathways. A contactable physician reported a 58-year-old male patient of an unspecified ethnicity started to receive gabapentin (unknown manufacturer), with an unspecified route of administration, therapy dates, dose, frequency and indication; and pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) via unspecified route of administration, on an unspecified date at a single dose for immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced allergy to gabapentin and pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein). The action taken in response to the event for gabapentin and pneumococcal vaccine was unknown and outcome of the event were unknown. Pfizer is a Marketing Authorization Holder for gabapentin and pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) in the reporter's country. This may be a duplicate report in cases where another Marketing Authorization Holder of gabapentin and pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) has submitted the same report to the regulatory authorities. Follow up (11Apr2018): New information via a Pfizer sponsored program Pfizer RXPathways from contactable physician includes: suspect drug details, event term update and course of events. Follow-up (20Apr2018): This is a follow-up report combining information from duplicate reports 2018152818 and 2018134102. The current and all subsequent information will be reported under manufacturer report number 2018134102. The new information reported from a contactable physician includes: co suspect vaccine was updated (from pneumococcal vaccine). The information on the batch number has been requested.
Information has been received from the mother of a male child with no past medical history and no known allergies who on 08/01/2000 was vaccinated with varicella virus vaccine. There was no concomitant therapy. The child was exposed to another child with chicken pox during the week of 04/01/2001. On approximately 04/07/2001, the child was tired and had swollen eyes. On 04/09/2001 the child developed a rash behind his ear, and on his face and neck. No medical attention was sought. Additional info has been requested.
In April, 1999 and May, 1999, the pt received her 1st and 2nd injection of Lymerix. In June, 1999, she experienced pain in her finger joints, which then spread to he ankles and toes. Treatment included prednisone and Vioxx to which she had some reactions (nos). The pt was given her 3rd injection of Lymerix on 11/3/1999 and her symptoms got immediately worse. Additional information has been requested.